Experts from the World Health Organization said they have recently received the vaccine data from Sinovac for emergency use assessment, with the report expected to be released in March.
Hong Kong has yet to approve the use of the Sinovac vaccine as they have not published its third-phase test data.
Sinovac earlier replied to media inquiries that the phase one and phase two clinical data of its vaccine have been published in international authoritative medical journals and have been approved for emergency use in China, Indonesia, Turkey, Brazil and Chile.
However, the data of its third phase of the study in various regions has not yet been published as it has to be peer-reviewed.
With the vaccine’s phase three clinical data still pending, Hong Kong’s original plan of procuring one million doses of vaccines from Sinovac has also been put on hold.
University of Hong Kong faculty of medicine dean, Gabriel Leung Cheuk-wai, also a member of the government’s advisory panel on COVID-19 vaccines, said they expect Sinovac to submit the relevant data to Hong Kong authorities in the coming few weeks for assessment.
Another panel member, David Hui Shu-cheong, said the panel will also take in WHO’s report for consideration while approving the Sinovac vaccines.
“It is important for the Sinovac vaccines to pass WHO’s assessment, so that we in Hong Kong can expedite the approval,” Hui added.